A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Trial end date:
2014-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the two treatment strategies; first-line combination
therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil)
in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first
clinical failure event.